Alterity Therapeutics Limited (ATH.AX)
AUD 0.01
(-10.0%)
AUD 0.01
(-10.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 23.4 Million AUD | 34.91% |
| 2023 | 17.34 Million AUD | -1.08% |
| 2022 | 17.53 Million AUD | -9.17% |
| 2021 | 19.3 Million AUD | 91.77% |
| 2020 | 10.06 Million AUD | -19.28% |
| 2019 | 12.47 Million AUD | 12.4% |
| 2018 | 11.09 Million AUD | 63.86% |
| 2017 | 6.77 Million AUD | -20.21% |
| 2016 | 8.48 Million AUD | -20.02% |
| 2015 | 10.61 Million AUD | -14.48% |
| 2014 | 12.4 Million AUD | 62.42% |
| 2013 | 7.64 Million AUD | -2.62% |
| 2012 | 7.84 Million AUD | 29.97% |
| 2011 | 6.03 Million AUD | 18.0% |
| 2010 | 5.11 Million AUD | -41.31% |
| 2009 | 8.71 Million AUD | -34.09% |
| 2008 | 13.22 Million AUD | 15.03% |
| 2007 | 11.49 Million AUD | -5.57% |
| 2006 | 12.17 Million AUD | -15.74% |
| 2005 | 14.44 Million AUD | 29.05% |
| 2004 | 11.19 Million AUD | 99.82% |
| 2003 | 5.6 Million AUD | -3.22% |
| 2002 | 5.78 Million AUD | 64.62% |
| 2001 | 3.51 Million AUD | 733.56% |
| 2000 | 421.93 Thousand AUD | 627.42% |
| 1999 | -80 Thousand AUD | -11494.2% |
| 1998 | -690.00 AUD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q4 | 15.02 Million AUD | 0.0% |
| 2024 FY | 23.47 Million AUD | 35.3% |
| 2024 Q2 | 8.44 Million AUD | 0.0% |
| 2023 FY | 17.34 Million AUD | -1.08% |
| 2023 Q4 | 7.72 Million AUD | 0.0% |
| 2023 Q2 | 10.69 Million AUD | 0.0% |
| 2022 Q4 | 10.43 Million AUD | 0.0% |
| 2022 Q2 | 10.13 Million AUD | 0.0% |
| 2022 FY | 17.53 Million AUD | -9.17% |
| 2021 FY | 19.3 Million AUD | 91.77% |
| 2021 Q4 | 9.83 Million AUD | 0.0% |
| 2021 Q2 | 9.6 Million AUD | 0.0% |
| 2020 Q1 | 3.7 Million AUD | -68.18% |
| 2020 FY | 10.06 Million AUD | -19.28% |
| 2020 Q2 | 7.54 Million AUD | 103.58% |
| 2020 Q3 | 2.85 Million AUD | -62.11% |
| 2020 Q4 | 6.23 Million AUD | 118.18% |
| 2019 Q3 | 4.66 Million AUD | -39.84% |
| 2019 Q1 | 3.87 Million AUD | -39.24% |
| 2019 Q4 | 11.63 Million AUD | 149.61% |
| 2019 FY | 12.47 Million AUD | 12.4% |
| 2019 Q2 | 7.75 Million AUD | 100.0% |
| 2018 Q3 | 3.18 Million AUD | -36.09% |
| 2018 Q2 | 4.98 Million AUD | 100.0% |
| 2018 FY | 11.09 Million AUD | 63.86% |
| 2018 Q4 | 6.37 Million AUD | 100.0% |
| 2018 Q1 | 2.49 Million AUD | -50.18% |
| 2017 Q1 | 2.72 Million AUD | -59.9% |
| 2017 Q3 | 2.5 Million AUD | -54.03% |
| 2017 Q2 | 5.44 Million AUD | 100.0% |
| 2017 FY | 6.77 Million AUD | -20.21% |
| 2017 Q4 | 5 Million AUD | 100.0% |
| 2016 Q4 | 6.79 Million AUD | 100.0% |
| 2016 Q2 | 5.59 Million AUD | 100.0% |
| 2016 Q3 | 3.39 Million AUD | -39.26% |
| 2016 Q1 | 2.79 Million AUD | -62.98% |
| 2016 FY | 8.48 Million AUD | -20.02% |
| 2015 FY | 10.61 Million AUD | -14.48% |
| 2015 Q2 | 4.57 Million AUD | 100.0% |
| 2015 Q3 | 3.77 Million AUD | -17.39% |
| 2015 Q4 | 7.55 Million AUD | 100.0% |
| 2015 Q1 | 2.28 Million AUD | -80.44% |
| 2014 Q2 | 9.34 Million AUD | 100.0% |
| 2014 FY | 12.4 Million AUD | 62.42% |
| 2014 Q3 | 5.84 Million AUD | -37.53% |
| 2014 Q1 | 4.67 Million AUD | -16.84% |
| 2014 Q4 | 11.68 Million AUD | 100.0% |
| 2013 Q3 | 2.81 Million AUD | -56.71% |
| 2013 Q4 | 5.62 Million AUD | 100.0% |
| 2013 Q1 | 3.24 Million AUD | 0.0% |
| 2013 FY | 7.64 Million AUD | -2.62% |
| 2013 Q2 | 6.49 Million AUD | 100.0% |
| 2012 FY | 7.84 Million AUD | 29.97% |
| 2011 FY | 6.03 Million AUD | 18.0% |
| 2010 FY | 5.11 Million AUD | -41.31% |
| 2009 FY | 8.71 Million AUD | -34.09% |
| 2008 Q1 | - AUD | 100.0% |
| 2008 FY | 13.22 Million AUD | 15.03% |
| 2008 Q4 | -13.22 Million AUD | 0.0% |
| 2008 Q3 | - AUD | -100.0% |
| 2008 Q2 | 3.84 Million AUD | 0.0% |
| 2007 FY | 11.49 Million AUD | -5.57% |
| 2007 Q4 | -11.49 Million AUD | 0.0% |
| 2007 Q3 | - AUD | -100.0% |
| 2007 Q2 | 3.83 Million AUD | 0.0% |
| 2007 Q1 | - AUD | 100.0% |
| 2006 Q3 | - AUD | -100.0% |
| 2006 Q2 | 3.18 Million AUD | 0.0% |
| 2006 Q1 | - AUD | 100.0% |
| 2006 FY | 12.17 Million AUD | -15.74% |
| 2006 Q4 | -12.17 Million AUD | 0.0% |
| 2005 Q3 | - AUD | -100.0% |
| 2005 Q4 | -14.44 Million AUD | 0.0% |
| 2005 FY | 14.44 Million AUD | 29.05% |
| 2005 Q2 | 3.17 Million AUD | 0.0% |
| 2005 Q1 | - AUD | 100.0% |
| 2004 Q4 | -11.19 Million AUD | 0.0% |
| 2004 Q1 | - AUD | 100.0% |
| 2004 FY | 11.19 Million AUD | 99.82% |
| 2004 Q3 | - AUD | -100.0% |
| 2004 Q2 | 2.51 Million AUD | 0.0% |
| 2003 Q4 | -5.6 Million AUD | 0.0% |
| 2003 Q1 | - AUD | 0.0% |
| 2003 Q2 | 1.83 Million AUD | 0.0% |
| 2003 FY | 5.6 Million AUD | -3.22% |
| 2003 Q3 | - AUD | -100.0% |
| 2002 FY | 5.78 Million AUD | 64.62% |
| 2001 FY | 3.51 Million AUD | 733.56% |
| 2000 FY | 421.93 Thousand AUD | 627.42% |
| 1999 FY | -80 Thousand AUD | -11494.2% |
| 1998 FY | -690.00 AUD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Anatara Lifesciences Ltd | 710.21 Thousand AUD | -3195.71% |
| BTC Health Limited | -1.03 Million AUD | 2352.968% |
| CSL Limited | 7.56 Billion AUD | 99.69% |
| Clarity Pharmaceuticals Ltd | 56.3 Million AUD | 58.43% |
| Clinuvel Pharmaceuticals Limited | 31.29 Million AUD | 25.211% |
| Island Pharmaceuticals Limited | 4.12 Million AUD | -467.386% |
| Orthocell Limited | 15.36 Million AUD | -52.293% |
| Proteomics International Laboratories Limited | 892.14 Thousand AUD | -2523.648% |
| Race Oncology Limited | 14.77 Million AUD | -58.469% |
| Starpharma Holdings Limited | 22.81 Million AUD | -2.589% |
| AdAlta Limited | 6.76 Million AUD | -245.766% |
| Zelira Therapeutics Limited | 5.94 Million AUD | -293.488% |
| Memphasys Limited | 3.67 Million AUD | -536.331% |
| NeuroScientific Biopharmaceuticals Limited | 1.96 Million AUD | -1091.046% |
| Acrux Limited | 8.55 Million AUD | -173.762% |
| Bio-Gene Technology Limited | 2.76 Million AUD | -747.757% |
| Botanix Pharmaceuticals Limited | 601.82 Thousand AUD | -3789.317% |
| Cynata Therapeutics Limited | 11.12 Million AUD | -110.424% |
| Nyrada Inc. | 4.55 Million AUD | -413.849% |
| PharmAust Limited | 6.65 Million AUD | -251.611% |
| Radiopharm Theranostics Limited | 299.22 Thousand AUD | -7722.36% |
| Arovella Therapeutics Limited | 10.78 Million AUD | -117.024% |
| Amplia Therapeutics Limited | 8.43 Million AUD | -177.471% |
| Biome Australia Limited | 7.91 Million AUD | -195.867% |
| Biotron Limited | 5.11 Million AUD | -357.996% |
| Chimeric Therapeutics Limited | 19.76 Million AUD | -18.411% |
| EZZ Life Science Holdings Limited | 39.57 Million AUD | 40.854% |
| Immutep Limited | 42.87 Million AUD | 45.407% |
| Imugene Limited | 135.09 Million AUD | 82.673% |
| Invex Therapeutics Ltd | 3.34 Million AUD | -599.567% |
| Noxopharm Limited | 7 Million AUD | -234.372% |
| Patrys Limited | 4.93 Million AUD | -374.462% |
| Prescient Therapeutics Limited | 10.89 Million AUD | -114.764% |
| PYC Therapeutics Limited | 60.91 Million AUD | 61.576% |
| Telix Pharmaceuticals Limited | 269.26 Million AUD | 91.307% |
| Dimerix Limited | 25.64 Million AUD | 8.722% |
| Hexima Limited | 1 Million AUD | -2220.366% |
| Neuren Pharmaceuticals Limited | 32.69 Million AUD | 28.413% |
| Nanollose Limited | 12.5 Thousand AUD | -187138.541% |
| Tissue Repair Ltd | 6.66 Million AUD | -251.093% |
| AnteoTech Limited | 12.18 Million AUD | -92.063% |
| Paradigm Biopharmaceuticals Limited | 65.1 Million AUD | 64.047% |
| Recce Pharmaceuticals Ltd | 21.68 Million AUD | -7.942% |
| Avecho Biotechnology Limited | 4.54 Million AUD | -414.954% |
| Actinogen Medical Limited | 22.77 Million AUD | -2.794% |
| Immuron Limited | 9.13 Million AUD | -156.149% |
| Argenica Therapeutics Limited | 8.26 Million AUD | -183.061% |